Oil Refineries
AstraZeneca may be subject to further import tax penalties from China
AstraZeneca said on Tuesday that it could face a fine up to $8,000,000 for suspected unpaid import tax in China. The drugmaker is working to boost its business in China, its second largest market, after scandals such as the arrest of the company's China president last summer. AstraZeneca, despite having a robust pipeline, is facing headwinds from its two largest markets: the United States and China. These include scandals in China and possible U.S. Tariffs on pharmaceuticals, as well as a trade conflict between Beijing and Washington. AstraZeneca reported that authorities in Shenzen had informed it that the unpaid amount...